一品红：全资子公司获得左卡尼汀口服溶液注册证书

Core Viewpoint - The approval of the drug registration certificate for L-carnitine oral solution marks a significant milestone for the company, enhancing its product pipeline and competitiveness in the chronic disease medication sector [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for L-carnitine oral solution [1] - The L-carnitine oral solution is indicated for the treatment of primary systemic carnitine deficiency [1] - The expected sales scale for this product in public hospitals in urban and county-level areas in China is approximately 1.257 billion RMB in 2024 [1] Group 2: Market Impact - The registration certificate enables the company to sell this specific drug in the domestic market, which is anticipated to positively impact sales [1] - The introduction of this product will further enrich the company's product categories, strengthening its position in the chronic disease medication market [1]